Search results for "RELAPSE"

showing 10 items of 110 documents

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Re…

2021

Abstract Background: Multiple myeloma (MM) is a heterogenous cancer of terminally differentiated plasma cells that typically express elevated levels of antiapoptotic proteins, such as BCL-2. Venetoclax (Ven), a highly selective, potent, oral BCL-2 inhibitor, induces apoptosis in MM cells, and when combined with bortezomib and dexamethasone showed promising efficacy in patients (pts) with relapsed/refractory MM (RRMM; Moreau et al. Blood. 2017;130:2392-2400). The Phase 3 BELLINI study primary analysis showed significantly improved response rates and progression-free survival (PFS) in pts with RRMM treated with Ven added to bortezomib and dexamethasone versus placebo (Pbo); however, increased…

Oncologymedicine.medical_specialtybusiness.industryBortezomibVenetoclaxImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseasePlaceboBiochemistrychemistry.chemical_compoundchemistryInternal medicineRelapsed refractorymedicineOverall survivalbusinessDexamethasoneMultiple myelomamedicine.drugBlood
researchProduct

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 …

2019

Introduction In MCL, progression-free survival (PFS) generally declines with each successive line of chemoimmunotherapy (CIT). We have previously published that with ibrutinib, a first-in-class oral inhibitor of Bruton's tyrosine kinase and a standard of care treatment (tx) for R/R MCL, median PFS exceeded 2 years (yrs) when used at first relapse (Rule S, et al. Haematologica. 2018;104:e211-e214). Here we present an updated pooled analysis with 15 months (mos) of additional follow-up, and for the first time, a comparison of outcomes with ibrutinib versus the prior regimen. Methods Patients (pts) enrolled in SPARK (MCL2001; NCT01599949), RAY (MCL3001; NCT01646021), and PCYC-1104 (NCT01236391…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologymedicine.diseaseBiochemistryCytokine release syndromechemistry.chemical_compoundRegimenPooled analysischemistryInternal medicineIbrutinibRelapsed refractoryLong term outcomesmedicineVindesineMantle cell lymphomabusinessmedicine.drugBlood
researchProduct

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relaps…

2021

Abstract Background Several therapies are recommended by NCCN/ESMO guidelines for autologous stem cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). In the single-arm, Phase II L-MIND study (NCT02399085), the chemotherapy-free regimen tafasitamab + lenalidomide (LEN) demonstrated efficacy for this patient population. In the absence of randomized clinical trial data, RE-MIND2 (NCT04697160), an observational, retrospective cohort study, compared patient outcomes from L-MIND with matched patient populations treated with NCCN/ESMO recommended therapies for ASCT-ineligible patients with R/R DLBCL. Methods Data were retrospectively col…

Oncologymedicine.medical_specialtybusiness.industryImmunologyRetrospective cohort studyCell BiologyHematologymedicine.diseaseBiochemistryInternal medicineRelapsed refractorymedicineObservational studyCar t cellsbusinessDiffuse large B-cell lymphomaLenalidomidemedicine.drugBlood
researchProduct

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

2021

Chronic myeloid leukemia; BCR-ABL1 transcripts; Response to imatinib Leucemia mieloide crónica; Transcripciones de BCR-ABL1; Respuesta al imatinib Leucèmia mieloide crònica; Transcripcions BCR-ABL1; Resposta a imatinib The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response …

Oncologymedicine.medical_specialtyrelapse-free survivalLeucèmia mieloide<i>BCR</i><i>-ABL1</i> transcriptsLeucèmia mieloide crònica:Organic Chemicals::Amides::Benzamides::Imatinib Mesylate [CHEMICALS AND DRUGS]survivalArticleOncología:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myelogenous Chronic BCR-ABL Positive [DISEASES]03 medical and health sciencesBcr abl10302 clinical medicineAnàlisi de supervivència (Biometria)chronic myeloid leukemiaInternal medicinehemic and lymphatic diseasesresponse to imatinibmedicineOverall survivalHematologíaCumulative incidenceBCR-ABL1 transcriptsGene transcriptbusiness.industryRMyeloid leukemiaImatinibGeneral MedicineExpressió gènica:técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Myeloid leukemia030220 oncology & carcinogenesisMolecular ResponseImatinib:compuestos orgánicos::amidas::benzamidas::mesilato de imatinib [COMPUESTOS QUÍMICOS Y DROGAS]MedicineRemission rateGene expression:Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis [HEALTH CARE]business:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES]030215 immunologymedicine.drugdiscontinuation
researchProduct

Functional Connectivity of Nucleus Accumbens and Medial Prefrontal Cortex With Other Brain Regions During Early-Abstinence Is Associated With Alcohol…

2021

Background: Alcohol dependence (AD) is a chronic recurrent brain disease that causes a heavy disease burden worldwide, partly due to high relapse rates after detoxification. Verified biomarkers are not available for AD and its relapse, although the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) may play important roles in the mechanism of addiction. This study investigated AD- and relapse-associated functional connectivity (FC) of the NAc and mPFC with other brain regions during early abstinence.Methods: Sixty-eight hospitalized early-abstinence AD male patients and 68 age- and education-matched healthy controls (HCs) underwent resting-functional magnetic resonance imaging (r-f…

Oncologymedicine.medical_specialtyrest-functional magnetic resonance imaginglcsh:RC435-571media_common.quotation_subjectalcohol dependencepredictorNucleus accumbensbehavioral disciplines and activitiesGyrusInternal medicinelcsh:PsychiatrymedicinePrefrontal cortexmedia_commonOriginal ResearchPsychiatryrelapsemedicine.diagnostic_testbusiness.industryAddictionAlcohol dependencefunctional connectivityrelapse severityMagnetic resonance imagingAbstinencePsychiatry and Mental healthmedicine.anatomical_structurenervous systemFunctional magnetic resonance imagingbusinesspsychological phenomena and processesFrontiers in Psychiatry
researchProduct

Psychopharmakotherapie in Schwangerschaft und Stillzeit

1998

The primary purpose of this article is to review critically the literature on the use of psychotropic medications in pregnancy and during breast feeding in order to suggest strategies for the clinical management of these periods. Use of psychotropic medications during pregnancy may cause three complications: 1. teratogenicity, 2. perinatal syndromes (neonatal toxicity), and 3. postnatal behavioural sequelae (behavioural toxicity). The literature features few well-controlled studies concerning these points, so that the available information allows only few conclusions. Exposure to certain psychotropic drugs in utero may increase the risk for some specific congenital anomalies; there is mostl…

Pediatricsmedicine.medical_specialtyPregnancyDrug discontinuationbusiness.industryBehavioural toxicitymedicine.diseasePsychiatry and Mental healthNeurologyPsychotropic drug useToxicitymedicineNeurology (clinical)Relapse riskbusinessBreast feedingFortschritte der Neurologie · Psychiatrie
researchProduct

Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica.

2017

Background: Up to every fourth woman with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) suffers a clinically relevant relapse during pregnancy. High doses of steroids bear some serious risks, especially within the first trimester of pregnancy. Immunoadsorption (IA) is an effective and more selective treatment option in disabling MS relapse than plasma exchange. Data on the use of IA during pregnancy and breastfeeding are scarce. Methods: In this retrospective multicenter study, we analyzed the safety and efficacy of IA treatment in acute relapses during pregnancy or breastfeeding. The primary outcome parameter - change of acute relapse-related disability after IA…

Pediatricsmedicine.medical_specialtybreastfeedingBreastfeeding030204 cardiovascular system & hematologymultiple sclerosislcsh:RC346-42903 medical and health sciences0302 clinical medicineplasma exchangeHigh dosesMedicineIn patientSpectrum disorderImmunoadsorptionlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyrelapsePregnancytherapyNeuromyelitis opticabusiness.industryMultiple sclerosisneuromyelitis optica spectrum disordermedicine.diseaseeye diseasesNeurologyNeurology (clinical)pregnancybusiness030217 neurology & neurosurgeryimmunoadsorptionTherapeutic advances in neurological disorders
researchProduct

Expression of the Sonic Hedgehog Embryonic Signalling Pathway Components in Matched Pre-Treatment and Relapsed Small Cell Lung Cancer Biopsies

2021

Abstract Cancer stem cells may be responsible for tumour regrowth and acquisition of resistance in small cell lung cancer (SCLC). The Hedgehog pathway regulates survival and proliferation of tissue progenitor and stem cell populations, promoting the expression of stem cell related and proliferative genes. We evaluated the Sonic Hedgehog (Shh) embryonic signalling pathway in relapsed SCLC. Expression levels of Shh related genes GLI1, SMO, SUFU, PTCH1, HHIP, BCL2, BMI, ZEB1, ZEB2, N-MYC, Twist1 were analysed by qRT-PCR in matched pre-treatment and relapsed tumour fresh frozen biopsies of three SCLC patients. Expression of each gene was compared using the paired samples t-test, as well as comp…

Pre treatmentbiologybiology.proteinCancer researchSonic hedgehogEmbryonic stem cellRelapsed Small Cell Lung CancerHedgehog signaling pathwayProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct

Allergic diseases of the skin and drug allergies – 2015. Randomized controlled, double blind trial of topical twice weekly fluticasone propionate mai…

2013

Allergic diseases of the skin and drug allergies – 2015. Randomized controlled, double blind trial of topical twice weekly fluticasone propionate maintenance treatment to reduce risk of relapse in mild or moderate atopic dermatitis in children Elena Rubio, Inocencia Martinez-Mir, Francisco J Morales-Olivas, Antonio Martorell-Aragones, Vicente Palop Larrea, Alejandro Bernalte Sese, Juan C Cerda Mir, Pedro Polo Martin, Isabel Febrer, Laura Aranda Grau, Inmaculada Llosa Cortes, Maria Jose Tejedor Sanz, Juan C Julia Benito, Teresa Alvarez De Laviada, Maria Victoria Planelles Cantarino, Esther Apolinar Valiente, Mercedes Loriente Tur, Antonio M Abella Bazataqui, Irene Alvarez Gonzalez, Cristina …

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAllergybusiness.industryImmunologyAtopic dermatitismedicine.diseaseFluticasone propionateDouble blindMeeting AbstractmedicineImmunology and AllergyRelapse riskbusinessmedicine.drugFluticasoneThe World Allergy Organization Journal
researchProduct

Riska novērtējums kā noziedzīga nodarījuma recidīva prognoze

2014

Mūsdienu sabiedrībā riska novērtēšana un vadīšana ir viens no nozīmīgākiem noziedzības kontroli organizējošiem ietvariem. Darba mērķis ir izpētīt riska novērtēšanas prakses recidīvās noziedzības prognozēšanai, izvērtēt prakšu radītās ietekmes, raksturojot to veidošanās un uzturēšanas vēsturisko, sociālo, kultūras un politisko kontekstu. Riska fenomena analīzē izmantotas dažādas riska socioloģijas teorijas, sniegts izklāsts par riska novērtēšanas prakšu veidošanos un attīstīšanos citur pasaulē un Latvijā. Pētījumā ir veikta recidīvo noziedzību ietekmējošo faktoru izvērsta analīze, veidoti modeļi recidīva prognozēšanai un padziļināti analizētas riska novērtēšanas prakses. Tas atklāj daudzveid…

Relapse - Risk assessmentSocioloģija politoloģija antropoloģijaRecidīvs - Riska novērtējumsSocioloģijaPreventionApplied sociologyNoziedzības novēršanaLietišķā socioloģija
researchProduct